Risankizumab shows benefit after ustekinumab failure
-
May 19
Selective interleukin-23 inhibition produced meaningful remission rates in heavily pretreated patients with Crohn’s disease.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, review pancreatic cysts in a case-based approach.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Risankizumab shows benefit after ustekinumab failure
-
by Doug Brunk
Selective interleukin-23 inhibition produced meaningful remission rates in heavily pretreated patients with Crohn’s disease.
Experts offer roadmap for IBS-like symptoms in IBD remission
-
by Olivia Anderson
New Rome Foundation/IOIBD guidance defines "IBD with IBS-like symptoms" and recommends mechanism-based care over reflexive therapy escalation.
Risk of colorectal cancer and mortality in older adults by adenoma history
-
by Julia Cipriano
Findings “raise major questions” about how clinically relevant surveillance colonoscopy remains in older adults with prior adenomas.
Early ‘top-down’ therapy reduces Crohn’s disease complications
-
by Alun Evans
PROFILE follow-up data showed lower rates of surgery, hospitalization, and disease progression versus step-up treatment.
Study supports sex- and comorbidity-based cutoffs for stopping Barrett's surveillance
-
by Alun Evans
“Most physicians make future surveillance decisions heavily based on perceived risk for EAC without considering … life expectancy.”
